García-Azorín, David http://orcid.org/0000-0002-3132-1064
Moya-Alarcón, Carlota
Armada, Beatriz
Sánchez del Río, Margarita
Article History
Received: 26 January 2024
Accepted: 29 February 2024
First Online: 15 March 2024
Declarations
:
: The NHWS received approval from the Pearl Institutional Review Board. All the NHWS respondents provided informed consent electronically prior to their participation.
: NA.
: Within the past 24 months, Dr. García-Azorín has received personal compensation for consulting/advising from the World Health Organization. Non-profit board membership in the Spanish Society of Neurology, and the European Union of Medical Specialist section of Neurology. Research funding from the Regional Health Administration (Gerencia Regional de Salud SACYL) in Castilla y Leon, Carlos III Institute of Spain, and Eli-Lilly. Speaker/travel grants/ clinical trials participation for Teva, Allergan/Abbvie, Amgen, Eli Lilly, Lundbeck, Novartis, and Biohaven. BA and CMA are Pfizer employees. MSdR is the econd vicepresident of the European Headache Federation. She is speaker and has participated in clinical trials for Teva, Pfizer, Eli Lilly, Lundbeck, Allergan/Abbvie.